Introduction
AI Overview · plain answer
These are three real, de-identified patients treated at Fortis Memorial Research Institute, Gurugram. Each showed a large fall in a tumour marker — PSA in the two prostate-cancer cases, Chromogranin A in the neuroendocrine case — after Lu-177 therapy. Individual case results like these are selected examples and are not a guarantee or prediction of outcome for any other patient. For what happens across many patients, the pivotal trials (VISION, TheraP, NETTER-1) are the right guide and are linked below.
Case studies are useful because they show, concretely, what a treatment can do. They are also easy to over-read. A single striking result does not tell you how often that result occurs, how long it lasts, or whether it will happen for the next patient. We therefore present each case factually, then place it against the trial evidence that does answer those questions.
Important
This page is general medical information for education, not medical advice and not a treatment recommendation. The outcomes shown are individual and were achieved in carefully selected patients. Whether Lu-177 PSMA or PRRT is appropriate for any person depends on their specific cancer, current imaging, prior treatment and organ function, and is decided in a multidisciplinary review with full informed consent.
Case 1 — heavily pre-treated prostate cancer
| Patient |
60-year-old man (ref. NMT-CS-01) |
| Diagnosis |
Metastatic castration-resistant prostate cancer (mCRPC), spread to bone and to hilar & paratracheal lymph nodes |
| Prior treatment |
Extensively pre-treated — docetaxel and cabazitaxel chemotherapy, sipuleucel-T (Provenge), abiraterone (Zytiga), olaparib, an ATR inhibitor, and palliative radiotherapy to the thoracic spine |
| Symptoms before |
Radiating chest and pelvic pain, breathlessness on exertion, poor appetite, weight loss |
| Therapy given |
Lu-177 PSMA-617 radioligand therapy — 4 cycles, with renal-protection hydration — alongside enzalutamide under medical oncology |
| PSA response |
>1000 ng/mL at baseline → 531 after 2 cycles → 32.23 ng/mL after 4 cycles |
| Tolerability |
No dry mouth (xerostomia); no immediate post-infusion complications |
This man had progressed through almost every standard option for advanced prostate cancer before Lu-177 PSMA was considered. After four cycles his PSA fell from over 1000 to 32.23 ng/mL — a reduction of more than 97% — and clinically he became pain-free without regular analgesia, with better appetite and energy.
Whole-body PSMA images — pre-therapy vs after 2 and 4 cycles
Case 1 imaging: pre-therapy scan (PSA >1000), after 2 cycles (PSA 531), after 4 cycles (PSA 32.23 ng/mL). Scan images to be added.
What this case shows
A deep PSA response in a heavily pre-treated, late-line setting — the situation in which Lu-177 PSMA is best evidenced. In the VISION trial, in men who had already received an androgen-receptor pathway inhibitor and chemotherapy, Lu-177 PSMA improved median overall survival to 15.3 versus 11.3 months and produced a PSA50 response in about 46%[1]. A PSA fall is a biochemical marker of tumour response; it correlates with, but is not the same as, longer survival.
Case 2 — Lu-177 PSMA used first-line (an individualised decision)
| Patient |
77-year-old man (ref. NMT-CS-02) |
| Diagnosis |
Metastatic prostate carcinoma — treatment-naïve (no prior cancer therapy) |
| Symptoms before |
Left leg weakness and left hip pain, with some muscle wasting |
| Therapy given |
Lu-177 PSMA-617 — 2 doses, 8 weeks apart, with renal-protection hydration |
| PSA response |
>2000 ng/mL (Apr 2022) → 10.2 ng/mL (Jul 2022) |
| Imaging response |
PSMA-PET showed a good partial response, with significant reduction in PSMA uptake across most lesions |
| Tolerability |
No dry mouth or other notable side effects; pain, appetite and general condition improved |
In a treatment-naïve patient, two doses of Lu-177 PSMA were followed by a fall in PSA from over 2000 to 10.2 ng/mL and a good partial response on PSMA-PET, with marked symptom relief.
Important context — this is not standard first-line therapy
Lu-177 PSMA is not the standard first-line treatment for metastatic prostate cancer. Standard first-line care is androgen-deprivation therapy together with an androgen-receptor pathway inhibitor, often with chemotherapy. The approved, trial-validated role of Lu-177 PSMA is in PSMA-positive mCRPC after an androgen-receptor pathway inhibitor (and, in its earlier approval, after chemotherapy)[1][4]. In this patient it was used first-line as an individualised decision for his specific circumstances, and the response was striking. It is presented here as an exceptional single case — not as evidence that Lu-177 PSMA should replace standard first-line treatment.
PSMA-PET — before vs after 2 cycles
Case 2 imaging: pre-therapy PSMA-PET (PSA >2000) vs after 2 cycles (PSA 10.2 ng/mL), showing reduced PSMA uptake. Scan images to be added.
Case 3 — Lu-177 PRRT for a progressing neuroendocrine tumour
| Patient |
35-year-old man (ref. NMT-CS-03) |
| Diagnosis |
Metastatic well-differentiated neuroendocrine tumour (NET) |
| Prior treatment |
Sandostatin LAR (octreotide) 30 mg monthly for 6 months — symptoms persisted and disease progressed |
| Symptoms before |
Abdominal pain for 6 months |
| Therapy given |
Lu-177 DOTATATE PRRT — 3 doses at ~3-month intervals, with renal-protection hydration; well tolerated |
| Marker response |
Chromogranin A 353 → 132 after 3 cycles |
| Imaging response |
Interim Ga-68 DOTANOC PET/CT showed ~42% reduction in tumour volume |
This younger patient’s NET had progressed on a somatostatin analogue. After three cycles of Lu-177 DOTATATE PRRT, his Chromogranin A fell from 353 to 132, interim imaging showed roughly a 42% reduction in tumour volume, and his abdominal pain, appetite, energy and quality of life improved. He was discharged in a stable condition.
Ga-68 DOTANOC PET/CT — pre-therapy vs after 3 cycles
Case 3 imaging: pre-therapy (Chromogranin A 353) vs after 3 cycles of Lu-177 PRRT (Chromogranin A 132), ~42% tumour-volume reduction. Scan images to be added.
What this case shows
A textbook PRRT scenario: a somatostatin-receptor-positive NET progressing on a somatostatin analogue, then responding to Lu-177 DOTATATE. This is exactly the setting established by the NETTER-1 trial, where Lu-177 DOTATATE produced a large improvement in progression-free survival versus high-dose octreotide[5], and on which the FDA approval of Lutathera was based[6].
The three cases at a glance
| |
Case 1 |
Case 2 |
Case 3 |
| Cancer |
mCRPC (prostate) |
Metastatic prostate |
Neuroendocrine tumour |
| Setting |
Heavily pre-treated |
First-line (individualised) |
After SSA progression |
| Therapy |
Lu-177 PSMA ×4 |
Lu-177 PSMA ×2 |
Lu-177 PRRT ×3 |
| Marker |
PSA >1000 → 32.23 |
PSA >2000 → 10.2 |
CgA 353 → 132 |
| Imaging / clinical |
Symptom relief |
Partial response on PET |
~42% volume reduction |
What these results mean — and don’t
Read carefully, these cases are encouraging and honest at the same time:
- They are selected, individual examples. Case studies are chosen because they illustrate a point. They are not typical, average or guaranteed, and the responses here are larger than many patients experience.
- Markers are not the same as cure. PSA and Chromogranin A measure tumour activity; a fall signals response, not a cure. Lu-177 PSMA and PRRT are used to control advanced cancer, relieve symptoms and, in trials, extend survival.
- Selection is everything. Each patient was eligible because a scan — PSMA-PET for prostate cancer, Ga-68 DOTATATE/DOTANOC PET for the NET — showed the target the therapy needs. Without that, these therapies do not work.
- The trials answer “how often.” For population-level outcomes, see VISION and TheraP for Lu-177 PSMA[1][2] and NETTER-1 for PRRT[5], linked below.
If you have PSMA-PET or DOTATATE-PET imaging and reports already, the most useful next step is usually a Second Read — a structured review of whether a radioligand therapy is a reasonable option in your specific situation.
"A good case study is honest about its own limits. These three patients did well, and we are glad to show it — but the right question for any new patient is never ‘what happened to someone else,’ it is ‘what does my scan show, and what does the trial evidence predict for someone like me.’"
Dr. Dharmender Malik · Consultant, Nuclear Medicine, FMRI
Second Read · review of your scans
If you already have PSMA-PET or DOTATATE-PET imaging and reports, the nuclear medicine team at FMRI — Dr. Ishita B. Sen and Dr. Dharmender Malik — can review them and tell you whether Lu-177 PSMA or PRRT is a reasonable option, before any travel is arranged.
Request a Second Read · WhatsApp +91 8800 988936
For patients & families
Frequently asked questions
Q01Are these case-study results typical?
No. Case studies are individual, selected examples chosen to illustrate how a therapy can work. They are not typical, average or guaranteed, and the responses shown are larger than many patients experience. For what happens across many patients, the randomised trials are the right guide: VISION (Lu-177 PSMA) improved median overall survival to 15.3 versus 11.3 months, and NETTER-1 (Lu-177 DOTATATE PRRT) produced a major improvement in progression-free survival.
Q02Is Lu-177 PSMA used as a first-line treatment for prostate cancer?
Generally no. Standard first-line treatment for metastatic prostate cancer is androgen-deprivation therapy with an androgen-receptor pathway inhibitor, often with chemotherapy. Lu-177 PSMA is approved and trial-supported for PSMA-positive mCRPC after an androgen-receptor pathway inhibitor (and, in earlier approvals, after chemotherapy). Case 2 on this page describes first-line use; that was an individualised decision for that specific patient, not a recommendation that Lu-177 PSMA replace standard first-line therapy.
Q03What counts as a good PSA response to Lu-177 PSMA therapy?
A fall of 50% or more in PSA (a PSA50 response) is the usual marker of a good biochemical response; about 46% of treated patients achieved this in the VISION trial. PSA is a useful indicator of tumour activity, but a PSA fall is a biochemical marker, not the same as cure or a guaranteed gain in survival.
Q04What does a fall in Chromogranin A mean in a neuroendocrine tumour?
Chromogranin A is a blood marker often raised in neuroendocrine tumours. A fall during treatment usually indicates reduced tumour activity and can accompany symptom improvement; it is interpreted together with imaging such as a Ga-68 DOTATATE/DOTANOC PET scan. Like any single marker, it is one part of the picture rather than proof of cure.
Q05Do these responses mean the cancer is cured?
No. These cases show tumour response and symptom improvement measured by blood markers and imaging. Response and disease control are not the same as cure. Lu-177 PSMA and PRRT are used to control advanced cancer, relieve symptoms and, in trials, extend survival; they are not described as curative for metastatic disease.
Q06How are patients selected for Lu-177 PSMA or PRRT?
Selection depends on a diagnostic scan showing the target. For Lu-177 PSMA the patient needs a PSMA-PET scan confirming PSMA-positive disease; for PRRT a Ga-68 DOTATATE/DOTANOC PET confirms somatostatin-receptor-positive disease. Kidney and bone-marrow function, prior treatments and overall fitness are also assessed in a multidisciplinary review before therapy.
Q07How is patient privacy protected in these case studies?
All cases are de-identified: no names or identifying details are shown, and they are published in summary form for medical education, with appropriate patient consent. The aim is to share clinically useful information that cannot reasonably identify an individual.
Q08Can I get Lu-177 PSMA or PRRT therapy at FMRI Gurugram?
Yes. Lu-177 PSMA therapy and Lu-177 DOTATATE PRRT are delivered at the Department of Nuclear Medicine, Fortis Memorial Research Institute, Sector 44, Gurugram, under Dr. Ishita B. Sen and Dr. Dharmender Malik. Eligibility is decided by imaging, organ function and multidisciplinary review. You can request a Second Read of your existing scans before travelling. Contact the team on WhatsApp +91 8800 988936.
Evidence & references
For readers who want more than a single case, these are the pivotal studies and approvals behind Lu-177 PSMA therapy and PRRT. Open each in a new tab to read the source.
[1] VISION — Sartor O, de Bono J, Chi KN, et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021;385(12):1091-1103.
View source ↗[2] TheraP — Hofman MS, Emmett L, Sandhu S, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in mCRPC (TheraP): a randomised, open-label, phase 2 trial.
Lancet. 2021;397(10276):797-804.
View source ↗[3] PSMAfore — Morris MJ, Castellano D, Herrmann K, et al. 177Lu-PSMA-617 versus a change of androgen-receptor pathway inhibitor in taxane-naïve mCRPC. Phase 3 trial NCT04689828.
View source ↗[4] FDA — Approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for PSMA-positive mCRPC. U.S. Food & Drug Administration.
View source ↗[5] NETTER-1 — Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med. 2017;376(2):125-135.
View source ↗[6] FDA — Approval of Lutathera (lutetium Lu 177 dotatate) for GEP-NETs. U.S. Food & Drug Administration.
View source ↗
Source case records (de-identified): Case 1 (NMT-CS-01) ↗ · Case 2 (NMT-CS-02) ↗ · Case 3 (NMT-CS-03).
About the Author
Dr. Dharmender Malik
MBBS · MD (Nuclear Medicine) · Consultant, Department of Nuclear Medicine, Fortis Memorial Research Institute
Dr. Malik is a nuclear medicine physician at FMRI Gurugram working in PSMA and DOTATATE imaging and in Lu-177 and Ac-225 radioligand therapy, alongside Dr. Ishita B. Sen. He has a particular interest in patient selection, dosimetry and the honest communication of what theranostic therapies can and cannot do.